Rixathon®
ACTIVE PRINCIPLE:
rituximab
INDICATION:
Wegener's granulomatosis
microscopic polyangiitis
Rheumatoid Arthritis
Non-Hodgkin lymphoma
B-cell chronic lymphocytic leukemia
DATE:
31/07/2017
STATUS:
Authorized
ACTIVE PRINCIPLE:
rituximab
INDICATION:
Wegener's granulomatosis
microscopic polyangiitis
Rheumatoid Arthritis
Non-Hodgkin lymphoma
B-cell chronic lymphocytic leukemia
DATE:
31/07/2017
STATUS:
Authorized